GB2063469A - A conjugate for use in an immunoassay procedure - Google Patents

A conjugate for use in an immunoassay procedure Download PDF

Info

Publication number
GB2063469A
GB2063469A GB8033401A GB8033401A GB2063469A GB 2063469 A GB2063469 A GB 2063469A GB 8033401 A GB8033401 A GB 8033401A GB 8033401 A GB8033401 A GB 8033401A GB 2063469 A GB2063469 A GB 2063469A
Authority
GB
United Kingdom
Prior art keywords
conjugate
tag
antibody
porphyrin
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8033401A
Other versions
GB2063469B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisher Scientific Co LLC
Original Assignee
Fisher Scientific Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisher Scientific Co LLC filed Critical Fisher Scientific Co LLC
Publication of GB2063469A publication Critical patent/GB2063469A/en
Application granted granted Critical
Publication of GB2063469B publication Critical patent/GB2063469B/en
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A conjugate for use in the detection and quantification of antibodies and antigens in body fluids comprises an immunologically active compound having attached to it a tag which is a metallo porphyrin and is capable of catalyzing a chemiluminescent reaction. The conjugate may be an antibody or an antigen to which a metallo porphyrin tag is attached and preferably comprises immunoglobulin to which haemoglobin is attached through a bifunctional linking agent. The tag may be derived from haemoglobin, myoglobin or cytochrome C. In use of the conjugate in chemiluminescence immunoassay, a reaction product carrying the tag may be mixed with luminol-perborate solution and the light output measured.

Description

SPECIFICATION A conjugate for use in an immunoassay procedure This invention relates to conjugates for use in immunoassay procedures for the detection and quantification of anitbodies and antigens (including haptens) and other substances present in small amounts in body fluids.
Various test systems have been developed for the detection and quantification of antibodies, antigens and other substances present in small amounts of body fluids. The most sensitive are immunoassay procedures which take advantage of the fact that an antibody binds specifically to its antigen and the reaction obeys the mass action law, Ab + Ag - AbAg.
Several immunoassay techniques are currently employed which can be classified by their binding characteristics. The most common utilise competetive and sandwich binding. Regardless of the technique a conjugate tagged for detection must be employed. The most widely used tags are radioisotopes and the procedure is called radioimmunoassay (RIA). Other procedures using different tags include enzyme immunoassay (EIA) and fluorescent immunoassay (FIA).
Radioimmunoassays using as tags the radioactive isotopes i2S,i4 or 3H presently command the major share of the market because of their extremely high sensitivities, that is, their ability to detect 10-15 moles or less of antigen or antibody. Despite their high sensitivity, RIA's suffer from the following disadvantages: (1) the beta and gamma counters required for the readout system are expensive and require expensive upkeep by highly trained service persons, (2) supervisory personnel must be highly trained and licensed by the government for work with radioisotopes, (3) because of the radioactivity RIA's are effectively prohibited in many countries outside of the United States, (4) the high radioactivity required for an appropriate signal requires the use of short-lived isotopes, thus requiring the frequent resynthesis of tagged compounds, and (5) the short lives means that the signal to concentration of tag ratio is continually and rapidly changing requiring frequent recalibration for each assay.
Enzyme immunoassays require the use of complex biological materials with retention of their native activity. The procedures themselves are time consuming due to the slow nature of the readout reaction and do not always yield requisite high sensitivities.
Fluorescent systems have slightly lower sensitivity limits than radioimmunoassay systems and require long incubation periods. In addition, high and variable blanks are often encountered.
Chemiluminescence refers to light produced as a direct result of chemical change. It involves the transformation of the free energy of a chemical reaction into light energy. The chemical reaction must release sufficient energy to populate an excited energy state; the reaction pathway must favour the formation of the excited state product; and the excited state product must be capable of emitting a photon itself for transferring its energy to another molecule that can emit.
A well-known, highly efficient chemiluminescent reaction is the oxidation of luminol (5-amino2,3-dihydrophthalazine-1 ,4-dione) in a basic solution. The most frequently used oxidant is hydrogen peroxide in the presence of a catalyst such as Fe(CN)36, Cu(ll), and Co(ll). Other oxidants include perborate, hypochlorite, iodine, permanganate and oxygen.
Chemiluminescence has been utilised in immunoassay procedures. United States Patent Specification No. 4 104 029 discloses a procedure for the assay of pharmacologically immunologically and biochemically active compounds in biological fluids in which a ligand is labelled with a chemiluminescent material such as luminol. In addition, it is known that iron and specifically iron protoporphyrin compounds react with luminol in the presence of hydrogen peroxide or sodium perborate and a base to give an excited species which emits light with with high efficiency, (see Ewetz and Thore's'Factors Affecting the Specificity of the Luminol Reaction with Hematin Compounds, Analytical Biochemistry, 71, 564570 (1976)).
The present invention seeks to provide a fast, sensitive and objective immunoassay for antigens or antibodies, to eliminate radioisotope hazards and the need for highly trained personnel to eliminate the need for special facilities associated with isotope work, to utilise only simple instrumentation and provide fast readout and high sensitivity (up to 10-15 mole detection), and to provide a long-lived tagged immunoreagent which is of relatively low cost and of ready availability. Because of its universal reactivity, a conjugate according to the present invention is applicable to a number of different assay procedures.
According to one aspect of the present invention, there is provided a conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound to which a metallic porphyrin tag is attached. Any antibody or binding partner for an antibody including antigens and haptens may be used. Antibodies raised in animal species such as goats and rabbits are particularly suitable. Antigens such as hormones and blood plasma proteins and haptens are suitable. Immunoglobulin and particularly IgG is particularly useful because of its availability and because it acts as both an antigen and antibody. Antigens which naturally contain iron porphyrin such as haemoglobin, myoglobin and cytochrome C may be used as the entire conjugate.
Because the tag functions as a catalyst rather than a reactant, each tag produces a plurality of photons whereas a luminol tag would only produce a single photon. This results in two advantages, namely greater sensitivity and prolonged emission.
The metallo porphyrin tag may be a molecule containing a metallo porphyrin and particularly a protein containing iron porphyrin. It may be iron porphyrin itself such as hemin. Haemoglobin, myoglobin, cytochrome C and catalase are suitable.
The metallo porphyrin tag is attached to the antigen or antibody by means of known bifunctional linking agents such as syanuric chloride, acrylyl chloride, and glutaraldehyde.
The conjugate is useful in various immunoassay procedures to determine the concentration of an unknown in an analyte. Typically such procedures use a reagent, an analyte and a conjugate. In a competitive assay the reagent which is generally attached to a solid phase such as nylon or polystyrene must be a binding partner for the conjugate. The analyte may be a binding partner for the conjugate or the reagent but not both. In a sandwich type assay the conjugate and the reagent cannot be binding partners for each other. Both are binding partners for the analyte. The binding reactions can be shown graphically as follows: A.Competitive Assay
Reagent Analyte Conjugate (Solid Phase) -Ab + Ag-Tag (1) j -Ab + Abs + Ag-Tag + Ab5 + Ag-Tag -Ab - AS-TaS (2) -Ab + Ags + Ag-Tag ;b > + =1 -Ab - Ag, B. Sandwich Assay (3) -Ab Ag, - Ab'-Tag (3) a -Ab + Ag5 + Ab'-Tag 'Tage , Thus in a competitive assay the greater the amount of the unknown (Abs or Ags) in the analyte, the less conjugate which can react with the reagent. In a sandwich assay the opposite is true.As the amount of the unknown in the analyte increases the amount of conjugate which reacts with the reagent increases.
To determine the amount of the unknown in the analyte, the reagent is separated from the remaining reactants. It is for ease in separation that the reagent is generally attached to a solid phase.
After separation including thorough washing to make certain no unreacted conjugate remains, the reagent is mixed with a chemiluminescent reactant. Luminol is preferred because of its efficiency. Other chemiluminescent substances which may be used include tetrabis (dimethylamino) ethylene, luciferin, lucigenin (dimethyl diacridinum nitrate) and oxalyl chloride. As an oxidant sodium perborate is preferred.
However, other known catalysts may be used.
The metallic component of the tag in the conjugate will catalyze the chemiluminescent reaction.
The amount of light emission recorded in a standard manner gives a quantitative determination of the amount of conjugate which is bound to the reagent and, hence, the amount of unknown in the analyte.
The following examples serve to illustrate the invention but are not to be regarded as limiting: EXAMPLE 1 Competitive Assay of Human Immunoglobulin G A. Preparation of Reagent {Solid Phase) Nylon mesh was partially hydrolysed by treating in 2 NHCI at 370C overnight. The nylon was washed free of acid with 0.01 MNa2CO3, pH 10, and washed with water. The nylon was placed in a solution of 400 mg of 1 ethyl-3(3-dimethylaminopropyl)-carbodiimide in water, pH 3.7. The pH was maintained between 3.5 and 3.8. The activation reaction was continued at room temperature until the consumption of acid ceased. The nylon was rapidly washed two times with dilute HCI (pH 3.4 to 3.8).
Human immunoglobulin, dissolved in 50 mM NaCI, pH 3.4, to 10 mg of protein per ml, was added to the washed activated nylon and the pH was gradually raised to pH 7 over 60 minutes. The attachment reaction was allowed to proceed for 60 minutes at pH 7. The pH was adjusted to 7.2 to 7.4 and the composition was incubated for 4 hours.
The nylon was washed according to the following sequence: 2 M NaCI, two times; water; 10 mM phosphate buffer, pH 7.35, containing 0.3 M NaCI, 0.2% bovine serum albumin and 0.1% Tween 80, two times; phosphate buffered saline, two times; and water. The washed nylon-immunoglobulin reagent was air dried and used in 1 cm2 pieces as the solid phase in immunoassays.
B. Preparation of Conjugate An iron porphyrin-antibody conjugate was prepared as follows: Goat anti-human serum was partially purified by precipitation with ammonium sulphate, and dialyzed against saline. To 2 ml of this solution (100 mg protein), 30 mg of sodium bicarbonate and 2 ml of water was added. A solution of cyanuric chloride in dioxane, 4 mg/ml, was added to the rapidly stirring solution of globulin. After 2 minutes a solution of 1 00 mg of haemoglobin in 4 ml of water was added and the binding reaction was allowed to proceed for 18 hours at 250C.
After reaction, the mixture was charged onto a 1.5 x 100 cm column of polyacrylamide gel, Bio Gel P-200 (100-200 mesh) and elution performed with 0.002 N phosphate buffer, pH 7.0, containing 0.05 M sodium chloride and 0.02% sodium azide. In this way any unreacted haemoglobin could be removed from the conjugate. The fractions containing both haemoglobin and antibody activity were pooled and used as the conjugate.
C. Preparation of Chemiluminescent Reactants The chemiluminescent readout measurements were performed on an Aminoco Chem-Glo Photometer.
The following solutions were used for CL analyses: Luminol Stock Solution. To 2.00 mg of luminol and 32 mg of glucose was added 4 ml of 0.1 N sodium hydroxide. After complete dissolution of the luminol, the solution was made up to 100 ml with water. The solution was stored at 40C.
Luminol Working Solution. Each working day, 1.00 ml of the above solution and 10 ml of 0.1 N sodium hydroxide was made up to 100 ml with water.
Perborate Solution. Each working day, 77 mg of sodium perborate was dissolved in 100 ml of water.
Analyses of chemiluminescence were carried out as follows: In a shell vial was placed 0.5 ml of the test solution, made up in the luminol stock solution as described above. This was placed in the sample compartment of the Chem-Glo-Meter. To this was then added 0.1 ml of the perborate solution. The light output was taken as the maximum pen deflection shewn on the recorder. In most cases, an average of the results of three sample injections was used.
D. Assay Procedure An immunoassay was performed with the human immunoglobulin-nylon solid phase and the iron porphyrin-antibody conjugate.
Nylon discs (surface area = 1 sq. cm) were incubated with 0.4 ml of conjugate at various dilutions plus 0.1 ml of phosphate buffered saline or 0.4 ml of conjugate at various dilutions plus 0.1 ml of a solution of human immunoglobulin. All dilutions of conjugate and human immunoglobulin were made with phosphate buffered saline. After incubation for 60 minutes at room temperature, the solutions were aspirated and the nylon discs were washed successively with 4.5 ml of 0.5% BSA-O.05% Tween 20, 2 M NaCI-pH 9.0, BSA-Tween-20 and two times with 0.1 M phosphate pH 6.1 buffer.
After washing, individual discs were eluted with a luminol working solution. For this purpose, 3.0 ml of the luminol working solution was added to each tube and the tube plus contents was sonicated for five minutes. A 500 yl aliquot of the solution was introduced into a vial, placed in an appropriate instrument such as the Aminco Chem-Glo Photometer, reacted with a solution of sodium perborate and the resultant light output was recorded.
E. Results The results obtained are presented in Table I. Inhibition of conjugate uptake onto the insoluble nylon-human immunoglobulin is seen over a wide range of conjugate concentration and competing immunoglobulin concentrations.
TABLE I Soluble Nylon Conjugate Immunoglobulin Relative Sheet Conc. (mg/ml) Added (,up) Light Intensity A 0.1 0 4,300 B 0.1 0.1 2,885 C 0.04 0 1,995 D 0.04 0.1 1,245 E 0.04 100.0 202 F 0.02 0 1,490 G 0.02 0.1 364 H 0.01 0 1,125 0.01 0.1 182 J 0.000 0 52 EXAMPLE II Preparation of Haemoglobin-Antibody Conjugates A series of haemoglobin-antibody conjugates were prepared as shown in Table II.
TABLE II Activation Step Binding Step Product Composition Cyanuric a Volume Chloride Time Temp. Hemoglobin Hemoglobin Example mi mg sec. OC. mg Immunoglobulin IIA 4 4 120 25 400 0.83 B 4 8 120 25 400 0.65 C 4 4 120 25 100 0.63 D 4 4 600 25 100 0.74 E 4 8 120 25 100 Insoluble products F 4 2 120 25 100 0.49 G 4 1 120 25 100 0.19 H 10 4 10 0 100 1.34 10 4 1 0 100 1.07 J 10 2 10 0 100 0.90 K 20 4 10 0 100 1.05 L 4 4 10 0 100 1.73 a Molar ratio, determined from the amount of free haemoglobin and the amount of haemoglobin in the oligomer fraction as shown by analysis of gel filtration column as in Example I Conjugates were tested and both had CL catalyzing and immunological properties.Results similar to Example I were obtained in the immunoassay with conjugates Il-C and lI-L and nylon bound antibody from Example I.
EXAMPLE II Competitive Assay of Immunoglobulin in Human Serum Nylon bound human immunoglobulin, as prepared in Example I, and haemoglobulin conjugated to anti-immunoglobulin, Example Il-C, were incubated in the presence and absence of human serum.
Reduced light output was observed in the presence of human serum.
EXAMPLE IV DirectAssay of human Haemoglobin Antibody to human haemoglobin was partially purified by ammonium sulphate precipitation; dissolved to 12,ug protein/ml of 0.05 M sodium carbonate, pH 9.6 The antibody was adsorbed onto polystyrene tubes Falcon Number 2054) for 1 hour at 370C. The solid phase antibody tubes were treated with 0.5% bovine serum albumin for 30 minutes at 370C. and washed 2 times with 0.2% bovine serum albumin containing 0.5% Tween in buffered saline. The antibody tubes were incubated in the absence and in the presence of human haemoglobin for 30 minutes at room temperature and washed with the albumin-Tween buffered saline 3 times and chemiluminescence was measured as in Example Light emission was higher when haemoglobin was added to the tubes and proportional to the amount of haemoglobin present.
EXAMPLE V Immun.oassay of Myoglobin Antibody to myoglobin was adsorbed to polystyrene and immunoassays were performed as in Example IV with similar results.
EXAMPLE VI Sandwich Assay of Chorionic Gonadotropin A. Preparation of reagent Goat antibody to human chorionic gonadotropin (HCG) bound to nylon beads: partial hydrolysis of the nylon was accomplished with N HCI for 2 hours. The beads were washed and additional carboxyl groups were introduced by allowing the beads to react with an excess of maleic anhydride at a constant pH between pH 8 and 9 for 1 hour. The beads were washed and the carboxyl groups were activated with 2 g of water soluble carbodiimide at a constant pH of 4.5 to 5.2 for 30 minutes. Excess carbodiimide was removed and goat anti-HCG was bound to the beads for 3 hours at room temperature followed by 1 8 hours at 40C.The antibody beads were treated with 0.2% bovine serum albumin in buffered saline, washed and stored in bovine serum albumin in buffered saline at 40C prior to use.
B. Preparation of Conjugate An iron porphyrin containing peptide derived from cytochome C was prepared by pepsin digestion of cytochrome C, followed by acid precipitation and dialysis. This peptide, demonstrated a higher chemiluminescent yield per porphyrin molecule than cytochrome C itself. Goat antibody to HCG was partially purified by ammonium sulphate precipitation and digested with pepsin to produce (Fab')2 fragments which were purified by gel filtration on Sephadex O75 column. Thiol groups were introduced onto the antibody fragment using N-acetyhomocysteine thiolactone and the thiolated antibody fragment was separated from excess thiolating reagent by gel filtration over a Sephadex G-25 column.
The iron porphyrin peptide was activated for conjunction to the thiolated antibody fragment by introduction of maleimide moieties using m-maleimidobenzoyl N-hydroxysuccinimide ester followed by Sephadex G-25 filtration. The conjugate was prepared by mixing thiolated antibody fragment and maleimido-iron porphyrin peptide for one hour at room temperature followed by gel filtration on a Sephadex G-75 column.
Immunoassays using antibody to HCG bound to nylon beads and iron porphyrin conjugated to antibody fragments derived from antibody to HCG were performed.
C. Assay Procedure Nylon beads conjugated with antihuman lgG were placed in glass tubes and incubated 30 minutes at 370C with 2.5 I.U. of HCG in a solution of 0.2% bovine serum albumin in phosphate buffered saline or phosphate buffered saline alone. The solutions were then aspirated and the beads were washed with 0.5 M HEPES, 0.5 M NaCI, pH 7.2 and then incubated for 30 minutes at 370C with various dilutions of the conjugate in . & 0.5 M HEPES, 0.1 5 M NaCI, pH 7.2 buffer. After incubation at 370C for 30 minutes, the beads were once again washed and the beads were eluted with 0.5 ml of 0.10/0 sodium dodecyl sulphate for five minutes. Luminol was added and light emission was measured as in Example I. Table Ill shows results typical of this double antibody sandwich assay for an antigen.
TABLE Ill Dilution of Relative Tube HCG Added Conjugate Light Sensitivity 1 + 1:5 61.1 2 + 1:10 39.0 3 + 1:25 16.1 4 + 1:50 3.25 5 + 1:100 2.40 6 + 1.21 7 - 1:5 19.5 8 - 1:10 4.81 9 - 1:25 3.56 10 - 1:50 2.34 11 - 1:100 2.21 12 - 1.63 The data shows increased CL indicating increased uptake of conjugate in the presence of HCG over a wide range of conjugate dilutions.

Claims (11)

1. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound to which a metallo porphyrin tag is attached.
2. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antibody or a binding partner for an antibody to which a metallo porphyrin tag is attached.
3. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antibody to which an iron porphyrin tag is attached.
4. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an antigen to which an iron porphyrin tag is attached.
5. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising a protein to which a metallo porphyrin tag is attached.
6. A conjugate as claimed in claim 5 in which said protein is immunoglobulin or a hormone.
7. A conjugate as claimed in claim 5 or 6 in which the tag is an iron porphyrin.
8. A conjugate as claimed in claim 8 in which the iron prophyrin is derived from haemoglobin or myoglobin, or cytochrome C.
9. A conjugate for use in the detection and quantification of antibodies and antigens in body fluids by immunoassay procedures, said conjugate being capable of reacting with an antigen or an antibody or both and including a tag capable of catalyzing a chemiluminescent reaction comprising an antigen or an antibody to which a metallo porphyrin tag is attached.
1 0. A conjugate for use in the detection and quantification of antibodies and antigens in body fluids by immunoassay procedures, said conjugate being capable of reacting with an antigen or an antibody or both and including a tag capable of catalyzing a chemiluminescent reaction comprising immunoglobulin to which iron porphyrin derived from haemoglobin is attached.
11. A conjugate substantially as herein described with reference to the Examples.
11. A conjugate substantially as herein described with reference to the Examples.
12. An immunoassay procedure in which a conjugate as claimed in any preceding claim is detected by chemiluminescence.
13. An immunoassay procedure substantially as herein described with reference to the Examples.
New claims or amendments to claims filed on 28 Jan 1981 Superseded claims 1 to 13 New or amended claims:
1. A conjugate for use in an immunoassay procedure in which the conjugate is detectable by chemiluminescence, the conjugate comprising an immunological active compound attached to a metallo porphyrin tag with a bifunctional linking agent.
2. A conjugate as claimed in claim 1 in which the bifunctional linking agent is any one of cyanuric chloride, acrylyl chloride and glutaraldehyde.
3. A conjugate as claimed in claim 1 or 2 in which said immunological active compound is an antibody or a binding partner for an antibody.
4. A conjugate as claimed in claim 3 in which said binding partner for an antibody is an antigen.
5. A conjugate as claimed in claim 1 or 2 in which said immunological active compound is a protein.
6. A conjugate as claimed in claim 6 in which said protein is immunoglobulin.
7. A conjugate as claimed in claim 6 in which said protein is a hormone.
8. A conjugate as claimed in any preceding claim in which said metallo porphyrin is iron porphyrin.
9. A conjugate as claimed in claim 8 in which said iron porphyrin is hemoglobin or myoglobin or cytochrome C.
10. An immunoassay procedure comprising: treating an unknown immunologically active agent with a conjugate comprising an immunologically active compound to which a metallo porphyrin tag has been attached to form a complex; treating the complex with a chemiluminescent reactant; and measuring the amount of light emitted.
GB8033401A 1979-10-17 1980-10-16 Conjugate for use in an immunoassay procedure Expired GB2063469B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8560179A 1979-10-17 1979-10-17

Publications (2)

Publication Number Publication Date
GB2063469A true GB2063469A (en) 1981-06-03
GB2063469B GB2063469B (en) 1983-07-20

Family

ID=22192713

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8033401A Expired GB2063469B (en) 1979-10-17 1980-10-16 Conjugate for use in an immunoassay procedure

Country Status (5)

Country Link
JP (1) JPS5696249A (en)
CA (1) CA1135620A (en)
DE (1) DE3039157A1 (en)
FR (1) FR2468125B1 (en)
GB (1) GB2063469B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071991A2 (en) * 1981-08-10 1983-02-16 Bio-Diagnostics, Inc. Improved fluoro immuno assay system
US4707454A (en) * 1981-08-10 1987-11-17 Bio-Diagnostics, Inc. Fluorescent chlorophyll labeled assay reagents
WO1989001630A1 (en) * 1987-08-12 1989-02-23 Nemeth Peter Procedure for relieving cell mixtures and tissues of unwanted populations
GB2233451A (en) * 1989-06-27 1991-01-09 Tropix Inc Chemiluminescent enhancement
US5145772A (en) * 1986-07-24 1992-09-08 Tropix, Inc. Chemiluminescence enhancement of enzyme-activated decomposition of enzymatically cleavable chemiluminescent 1,2-dioxetanes
EP0812920A1 (en) * 1996-06-14 1997-12-17 Packard Instrument B.V. Use of porphyrins in instrumental detection methods
WO1998054578A1 (en) * 1997-05-29 1998-12-03 Bio-Rad Laboratories, Inc. Chemiluminescent hemoglobin assay
US6001573A (en) * 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0711522B2 (en) * 1989-09-13 1995-02-08 工業技術院長 Chemically amplified chemiluminescence immunoassay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244170A1 (en) * 1973-09-14 1975-04-11 Sibiem Colorimetric assay of biological material - by fixing colouring matter to the test material, and optically assaying soln
US4181650A (en) * 1975-08-25 1980-01-01 Maier Charles L Jr Procedure for the assay of pharmacologically immunologically and biochemically active compounds in biological fluids
US4220450A (en) * 1978-04-05 1980-09-02 Syva Company Chemically induced fluorescence immunoassay

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071991A2 (en) * 1981-08-10 1983-02-16 Bio-Diagnostics, Inc. Improved fluoro immuno assay system
EP0071991A3 (en) * 1981-08-10 1983-09-07 Bio-Diagnostics, Inc. Improved fluoro immuno assay system
US4707454A (en) * 1981-08-10 1987-11-17 Bio-Diagnostics, Inc. Fluorescent chlorophyll labeled assay reagents
US5145772A (en) * 1986-07-24 1992-09-08 Tropix, Inc. Chemiluminescence enhancement of enzyme-activated decomposition of enzymatically cleavable chemiluminescent 1,2-dioxetanes
WO1989001630A1 (en) * 1987-08-12 1989-02-23 Nemeth Peter Procedure for relieving cell mixtures and tissues of unwanted populations
GB2233451A (en) * 1989-06-27 1991-01-09 Tropix Inc Chemiluminescent enhancement
GB2233451B (en) * 1989-06-27 1993-09-15 Tropix Inc Chemiluminescence enhancement
EP0812920A1 (en) * 1996-06-14 1997-12-17 Packard Instrument B.V. Use of porphyrins in instrumental detection methods
US5998128A (en) * 1996-06-14 1999-12-07 Packard Instrument B.V. Use of porphyrins in instrumental detection methods
US6001573A (en) * 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label
WO1998054578A1 (en) * 1997-05-29 1998-12-03 Bio-Rad Laboratories, Inc. Chemiluminescent hemoglobin assay

Also Published As

Publication number Publication date
DE3039157A1 (en) 1981-08-27
GB2063469B (en) 1983-07-20
FR2468125B1 (en) 1985-08-23
CA1135620A (en) 1982-11-16
JPS5696249A (en) 1981-08-04
FR2468125A1 (en) 1981-04-30

Similar Documents

Publication Publication Date Title
US4375972A (en) Heterogeneous chemiluminescent immunoassays utilizing metallo porphyrin tag
US4478817A (en) Detecting or quantifying substances using labelling techniques
Blake et al. Use of enzymes in immunoassay techniques. A review
EP0594772B1 (en) Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5543332A (en) Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
EP0087959B1 (en) Enhanced luminescent and luminometric assay
US4859583A (en) Chemiluminescent immunochemical technique for low molecular weight antigens
US4959306A (en) Labeling design for a binding assay reagent
JPS60226900A (en) Nucleic acid-protein composite body
Johannsson Heterogeneous enzyme immunoassay
EP0640216B1 (en) Separation method
US5672475A (en) Mixed luminescent conjugate test
CA1135620A (en) Immunological compound attached to metallo-porphyrin tag
US4835101A (en) Luminescent analyses with enhanced storage stability
CA2164767C (en) Immunoassays for haptens and hapten tracer-antibody complex which can be used therefor, and process for the preparation thereof
Kato et al. Fluorophotometric enzyme immunoassay of thyroid-stimulating hormone
JPH0456257B2 (en)
US5196349A (en) Immunoassays for thyroid hormones using thyroglobulin
JPH02124462A (en) Improved immunity measuring method
AU582341B2 (en) Assay for immobilized reporter groups
EP0132292A2 (en) Method of measuring biological ligands
EP0480361A2 (en) Quantitation by chemiluminescence using photosenstive substance
JP3792899B2 (en) Chemiluminescent enzyme immunoassay method
JP4028645B2 (en) Chemiluminescent enzyme immunoassay method
KR960016337B1 (en) Reagent kit for use in sandwich immunoassay

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee